2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
Guide For Health Plans: Formulary Benchmarking
PSG Provides Insight To Support Your Formulary Strategy Health plans face increasing pressure to optimize formulary design in ways that balance clinical appropriateness, member…
Read Post
Flexible Procurement Design Supports Complex Benefit Structures
Two large employers were navigating the challenges of comparing traditional procurement options to a carved-out approach. PSG was able to help standardize the process…
Read Post
2026 Trends in Drug Benefit Design Report Webinar
PSG announces the results of its extensive research on the latest trends in drug benefit design. Plan sponsors face complex decisions and challenges…
Read Post
2026 Trends in Specialty Drug Benefits Report
PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to…
Read Post
PSG Report Finds Cost Management Remains Payers’ Top Goal as Coverage Strategy for New Drugs and Indications Emerges as Biggest Specialty Drug Management Challenge
New specialty drug benefits research shows growing focus on medical-benefit drugs, rising interest in trading rebates for utilization controls, and increasing scrutiny of PBMs’ management…
Read Post
2026 Drugs to Watch: New Approvals and Expanded Indications
PSG’s 2026 Drugs to Watch List: A Guide For Payers Key Points: PSG produces a focused list of new drugs expected to have the…
Read Post
Stopping a High-Cost Specialty Claim Before it Became a Long-Term Drain
A newly-initiated specialty medication costing more than $20,000 monthly went unnoticed by traditional reporting for an employer until it was identified by the PSG…
Read Post
Using Data as the Strategy Engine, Not Just as an Instrument of Validation
Rethinking What “Data-Driven Strategy” Means in Pharmacy Benefits Key Points Many leaders use data to validate strategy, but the greatest value emerges when analytics…
Read Post
Guide For Payers: Operationalizing Value in a Modular PBA Model
PSG Helps Execute Your Modular PBA Goals A Modular PBA model gives payers the flexibility to design pharmacy benefits around their specific goals, systems,…
Read Post
FTC Settlement With ESI, CAA 2026, and Proposed Rule: What Does It Mean For Plan Sponsors?
An Overview of Regulatory and Legislative Updates For Plan Sponsors Key Points The ESI settlement creates new options for plan sponsors, but few protections…
Read Post
Itvisma: New Multi-Million Dollar Gene Therapy Approved For Spinal Muscular Atrophy (SMA)
Will Additional SMA Gene Therapies Affect Payers’ Budgets? Key Points: SMA treatment has shifted from supportive care to high-cost disease-modifying and gene therapies, with…
Read Post